Atomic AI

Atomic AI is an RNA drug discovery company that combines machine learning with structural biology to develop next-generation RNA-centric medicines, including RNA-targeted small molecules and RNA-based therapeutics. Its proprietary ATOM-1 foundation model provides the world's most precise predictions of RNA structure and function, integrated into a virtuous cycle with purpose-built in-house wet-lab assays. This approach enables the identification of novel RNA targets, prediction of RNA folding and interactions, and rational design of RNA-targeting therapeutics for diseases with significant unmet need. The platform leverages deep learning trained on experimental RNA data to overcome the limitations of traditional structural biology methods. Founded in 2017 and headquartered in San Francisco, California, Atomic AI has raised $42M in Series A funding from investors including 8VC, Greylock Partners, Playground Global, AME Yahoo Ventures, and AIX Ventures.